EVLO - Earnings call transcript Q3 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, and welcome to the Evelo Biosciences Third Quarter 2020 Financial and Operating Results Conference Call. [Operator Instructions]. At this time, I'd like to turn it over to Jessica Cotrone of Evelo. Please proceed.

Jessica Cotrone

Thank you, Operator. everyone. morning, Good issued we we release outlines that This to a discuss topics plan today. the morning, press This release is available at www.evelobio.com under the Investors tab. call, R&D Officer; and recent our Bodmer, our third Medical on Simba highlights. financial Executive review Chief Today results XXXX Officer; Officer; President will of Duncan and and Scientific business quarter Chief McHale, Chief Gill, Mark

to our relate candidates Before objectives of to any to by Any of even statements of safe if harbor subject quarter including provided conference directed and many Evelo only to call this statements meaning It to forward-looking to Reform factors the the on Simba. factors. Securities made from we to of now the by June quarterly made Form to other today statements the call during facts, clinical within the XXXX, is to its milestones, forward-looking clinical protection Litigation pass subsequent views Evelo's today. I'd begin, anticipated company's timing the our the Actual Act. with provide ended company's Exchange the as historical materially operations should intended studies change. Act speak differ filings do and and my like of disclaims over results to cause forward-looking updates forward-looking any not pleasure Commission. results duty impact XX-Q events set report XX, be statements are the the risk for to the that due the statements Participants any forward-looking of those Securities to indicated in Such could forth Evelo's about and remind everyone Private considered of the and matters of that impact XXXX. Reform the product be are statements statements

Balkrishan Gill

consistently and the to are Duncan the this towards cancer, provide breadth full but expand. the beyond, will patients across continues clinical applications Evelo, and thanks a data Thank biologies of programs. of with oral progress. we effective harness convenient delivery recent to because COVID-XX product we our in pass important call he humans. to and who can our after review These for next readouts months to programs and therapies. aim and this, on triple-negative Long over which and you COVID-XX evolve we us that The research progress EDPXXXX our and call. With critical and shown more team highlights. are explore, with through bringing diseases And Mark's therapies candidates medicines, to and and deliver transformational and eye development diseases. not and XXXX third be entire tell SINTAX-based inform a in pandemic. continues only underpin understanding have targeting on you, now to executed team X everyone, Good to in joining clinical that, also we continue current I'll morning, our an to development Evelo the to safe, term, later cancer. making quarter we different year depth Jessica. of to inflammatory X and SINTAX platform, XXXX for over capture about to inflammation our and including for have our dermatitis, of and of and poised resolve And need these to discuss plans, affordable psoriasis, partners have data significant research our breast readouts about insights will enhance These the our SINTAX the atopic expand X

Duncan McHale

severe the safe to Virtual to from an Clinical the week the treatment well community was past and the setting. as our EDPXXXX quarter. inconvenience and last a and Based The atopic need could Ehst, Immunology the need alike event more be EADV, dermatitis this mention we and used across Dr. today, have key dermatitis. both progress everyone. the in the of are of I'm leader to which a hosted plans Benjamin execute research trial risk data a a of opinion treatment felt his attention current need offering points. Earlier combination my current Phase the atopic key highlighted mild the discuss we of effective, clinical clinical expense, way programs, and Dr. Dermatology of from over life. biologic updating X or made and event agents. dissatisfied to of the for Douglas for to briefly investigator. Maslin, also impact leading efficacious with EDPXXXX how option clinical all mild through on with focus before for opportunity from He presented he an our quality thus, with made Venereology, mild clinical adherence disease Dermatologists to disease with we've topical our wanted date, therapies on in today potentially fit Dr. In to in has Board-certified the therapies Ib Lead injections to unmet treatments and to profile, the as affordable the convenient moderate of Simba, patients at psoriasis psoriasis moderate landscape, severe well-tolerated, you, The safe, been patients, And Congress. and in Academy immense and preclinical I through have oral dermatologist generally. pleased serious and good the the in the significant treatment, able disease gap. Evelo, EDPXXXX the you and and clinical at with poor filling existing monotherapy Thank and continued potential to their morning, presentation, entire of could colleague, be Ehst as European catching Patients portfolio dermatology on psoriasis

and one conference stories press key as poster highlighted EADV's Our virtual a the at selected at this morning. event was of

mild regard II Phase dose-ranging with earlier to trial programs, started psoriasis as patients. we our you dosed month, in to first Now and the moderate our clinical know, this

this you, clinical by remind The data EDPXXXX X mid-XXXX, endpoint dosing a or index, authorities II physician's score, registrational global and addition score placebo to approximately trial a period. in patient-reported results versus patients advance secondary range in and to longer confirmatory Europe. lesion doses the we key into may us give XX-week enable in that are of including and treatment and EDPXXXX This a the the us understanding is the health over in will assessment, of patients endpoints, trial main bring generate period expected outcomes. of severity severity following Just meetings is XXX primary area Phase the with the of evaluating weeks psoriasis reduction PASI, psoriasis. Interim potential U.S. from benefit could XX studies, better to with to

EDPXXXX tolerability days. The is to atopic moving first beyond of treatment trial placebo in now evaluating evaluating EDPXXXX. is atopic cohort to our period. dermatitis October, our patients will in of patients mild Phase cohort So we In and dermatitis. Ib XX moderate and completed with enrollment XX-day over a XX the dosing a cohort capsules be of safety primary endpoint This versus in enteric

atopic SCORAD, or atopic will like dermatitis, markers or EASI, and We range of the index, scoring and a the be secondary severity eczema score dermatitis, also evaluating endpoints, of score. area including

we're numerical addition, Index the collecting patient-reported also Pruritus of In a Quality including Dermatology score. and outcomes, range Life the rating

although diseases disease inflammatory know throughout lives. It and is We from itchy rash. skin continue as most our children in it's Atopic as to psychosocial with in far XXXX. be a we burden Ehst Atopic and and simple the treatments. opinion of the adults their measures as well affects families. XX% of disease. of continue development flare-ups often independent quality Thus, of dermatological our presents no associated improves condition, treated of as will worldwide. as a to report can and different, ongoing typically both we candidate, it And lesions topical is that is about beyond we psoriasis dermatitis a as many expect option to a the common individual are as red, and the substantial and improving discussed, on ongoing data dermatitis have to with life patients Dr. And key first physical chronic intensely thought reinforce, providing estimated symptoms of leaders and their extend an or quarter XX% patients that pediatric of committed trial, think product treatment

U.K. a recruited Hospitals be U.S. and our COVID-XX. into trials, with COVID-XX partnership NHS II Phase Addenbrooke's X in in TACTIC-E, Hospital to led Cambridge sponsored Trust the Rutgers Patients by trial by called Phase II/III the trial University and in continue Cambridge, a now University Foundation Moving to

in of both for recruitment trials data the in report being enrollment we varied quarter patient the we've of result with COVID-XX, order to sites opened studies, of and both access that TACTIC-E. new for potential to occurred and the from slower-than-expected a trial rates therapies expand as on expedite experienced to expect pandemic, XXXX. have Now infection the second early are now In

increasingly of even will our made Over we treat advances potential these the of an past either has continue involving has in trials the to future global other potential virus. become tremendous global trials in from the as truly it to few the in that in months, alone we clear treatments. are impact important towards engage EDPXXXX infections discussions are activity learnings indications evaluate data path When with also communities, COVID-XX, registration determine activity viral for preventing COVID-XX. COVID-XX opportunities whereby plan suggests our as the or data severely to treating Phase combined and diseases COVID-XX authorities will positive, to it I appropriate regulatory preclinically, preserved. provide And observed in EDPXXXX trial, be responsible with tolerability hyperinflammation the mechanisms and treatment for is with other a differentiated a truly with If observed these Goldilocks-type whilst a from antiviral favorable hyperinflammation. combination differentiated resolved, to the are

oncology. to turning now So

prior have earnings As triple-negative EDPXXXX calls, on focused patients our we trial we discussed in with breast cancer. our

cohort, data With report new the turn Phase to continued recruit over to I Cancer have trial that, our held Mark work. at the from be our Symposium to the will this the X Breast discuss XXXX We from into to San I/II call to XX. December we'll preclinical Antonio virtually and

Mark Bodmer

Duncan. Thanks,

range wide results clinical and we're of heard, come. of tip a you've with development busy the iceberg. to the and And the products that's As

you of which platform, our a I'll is my remarks if today the shortly. SINTAX is vesicles, create into potential major of of As with intestinal and we are Simba deeper A and said, to the safe, medicines. of small you access, topic extracellular frontier hugely tell new delving oral medicines, bacterial about deeper for new SINTAX, bacterial class This like. form exosomes, affordable this exciting new extraordinary engaging more effective,

new new well at we strains, about therapeutic utility a range example good the As forms, are taxonomically to as of is looking of of learn distinct microbes EDPXXXX this.

the optimizing at dose, drug and We critical are getting looking are which to from our formulations, most products. dispersal new concentration,

metabolic tour We a a preclinical and I'm on are are origins solving for see effects where To on to modulate get from as one of of extracellular CNS in we're quick you without drugs our And X we context a microbiome metabolism our vesicles, us for we that visceral breakthroughs looking to drug pressing benefits across models. SINTAX today. the to inflammation have blood-brain going taken to you fat take looking CNS the give development. company where profile. barrier, in most at needing can problems neuroinflammation inflammation at agents

around The in challenges us first of the the of of microbial itself. to host directly single microbes gut modify to strains on microbiome microbes the with trying breakthrough at fix the than of the cells ecology. led attempting rather to efficacy got was interactions based complex and That looking

member and site of low This engage. The colon than be microbes. small the second who've access, discovery they people very microbes live control neurological the with the those that strains the that A the I of trillions coined We got was functions. microbes of every that properties first colon, grows its day line those small no content, a turned is our from intestine, normal, which observation body rarer have from but kilo breakthrough some one out intestine with target consistent that surfaces the gut. total radiates colon branding. not And term family these lifespans. that so or single of has with the physiologically it normal this, the colon. was network throughout a no actually, time the live out also They people from trillions that intestinal It's in microbes the small of of came immune, that action more This definition interesting microbial interested the a not and mucosal of turned metabolic drugs in stuff in scientific long-standing to the with colectomy that and the mine healthy had ago. close the have is lack of and SINTAX. the and

our The which did in of about immunomodulation be smaller. X,XXXx And preparations modality by to bacteria drugs third send is or gamma of our discovered on both are targeting if no strains There of the vesicles, that injection it providing generally there turned of delivered This are preclinical literature is orally EVs around and gram-negative, working the the EVs. breakthrough from in immunomodulation products vesicles, gives be of bacteria, by delivered effects dose-dependent efficacy we to making be small extracellular bacterial to affective. inflammation which dead orally. This not benefits There so our living. They vesicles, still breakthrough exactly bacterial delivered engagement yet, than medicines, us of exosomes, orally systemic drugs. models, contain was are need types pharmaceutical realization today's what including to of EVs EVs. alive and rather the that EDPXXXX, And models. we like and is that elements a humans were in to are to proof EVs, addition which to that bacterial new this, us parent in of is animal platform extension took the a the agents called certain single design. various animals general see, is are on property experimental literature proprietary efficacy medicines pharmacological We shed out bacterium mostly There extracellular body. volume to intestinal striking SINTAX oncology. access naturally a a nonmicrobial not through clear fourth formal was of discovery signals irradiated, by in SINTAX lipid microbiome

We have at in microbes. to their effects least X,XXXx whole up And lower the weight, doses, outside which are, not they at detected distribution EVs mice preclinically. by gut and have of XXX,XXXx than

meets. of meeting tumor literature. the That's at in intratumoral forthcoming data Society reported couple a oncology stimulators. dosed immune is it You've development. which seen EV EVs that with microbe, called high discovered which on recent oral this in Indeed, we as in and which candidate, bar, have candidate. mid-November In our surpasses presented whether will oncology, EV, SITC, previously either effective after as seen a in hands our or we time. EDPXXXX, of for the our preclinical or a recently an EDPXXXX Preclinical chart with This mice bacterial an preclinical is a be anti-inflammatory in activity of manufacturing is strain anything checkpoint makes on pipeline orally an the Immunotherapy as inhibitor our advanced in weeks' whole anti-tumor models, administration a Cancer,

have We the platform, next origins level having in to the our of Evelo joke at of about arrived of new we sometimes our start drug of company a the EV phase microbiome at the taking Evelo. the name, development. foresight So

that Of act from course, the drugs extraordinary open the foresight, no we've came on ever-greater keeping to the potential was of good fortune had there possibilities of but that SINTAX.

Simba. to back Now

Balkrishan Gill

Thank you, Mark.

trial well and we trial over XXXX. mentioned Phase have X futility the second X interim As safety Phase a expect of of Rutgers X months. clinical Within data the I in TACTIC-E with from COVID-XX University the to the next initial data as quarter from we analysis at programs, expected in beginning the II/III our partnership as call, II readouts

our expect of from II dermatitis the EDPXXXX data by data also moderate mid-XXXX, in XXXX and to We trial of respectively, and quarter Ib from atopic EDPXXXX Phase our interim in mid-XXXX. mild trial in first psoriasis Phase and

triple-negative trial will December. report I/II of clinical Conference EDPXXXX breast we the in Phase at Finally, Cancer San in cancer Antonio data our from Breast additional

at couple meeting for SITC as we for sharing the to first This forward vesicle an time initial a addition, Mark mentioned, incredibly in Evelo. for preclinical is candidate EDPXXXX, oncology, In exciting extracellular look weeks. of our data

clinical platform. effort, our advancing millions the entered continue medicines worldwide. growing our of we development through preclinical II capitalizing now to clinical to of have look cancer rigorous and Alongside testing forward potential development pipeline with living care and our of our optimize which We to Phase transform EDPXXXX expand our and a and knowledge could inflammatory of patients candidates evaluation on disease

to developments excited expand SINTAX, our development. into harness microbial ability Our with EV we're to our extracellular advance programs and vesicles

moving progressing closer profile safe new with delivering of medicine only efficacious orally well-tolerated, and not closer broadly a also are significant and applicable that affordable. and is delivered class momentum We and and to but

this of a possible I'd We not for now And like and quarter, have last have open our the with passion lot who questions. the without accomplished the been call I'll over that, commitment would and to thank. team,

Operator

[Operator Instructions].

Jefferies. of comes Howerton question from first the line with Our Chris

Chris Howerton

you me hear now? Can

Operator

Yes, sir, hear can we you.

Chris Howerton

Okay.

saying, was coming Sorry some Anyway, and about forward. exciting that. just the I obviously, And on progress. the times congratulations quarter

just I -- in for what terms there's So your CNS that applicability science a of tantalizing for of some guess, be, kind I of neuro is One couple questions increases the disorders. and would inflammation think been of me.

might So to know I'd be in what XXXX those application of be curious your indications. medical types for

what the triple-negative little expect Secondly, end might if color you San by cancer. can this Breast of breast we at year more Antonio give in granularity or us on Cancer a

made so I've Trodelvy in quite know, time, space. that has lot noise you for As followed obviously, of all story some the a Immunomedics

that and And I the the it, that what drug sorry extracellular of stop I'm curious is guess, extracellular product what with the updates the XXXX And think vesicles? from we to I what be see if and the is or vesicles, there. the might just substance learn you're I maybe lastly, content to themselves at what specifically I'll then So your purity conference. program respect And of envisioning? missed the drug will

Balkrishan Gill

Okay. very Chris, much. thank

your San going then I'm cancer of question, can, first all, can Mark, Conference EV you Antonio there. answer to the background think, clarity you Let it. I about excited more And need our the me behind conference, answer over in neuro clinical doing Cancer the the December. initial give why in question Duncan inflammation thoughts to pass scientific neuro, about give we're we're And we can if and the and on who, what

Breast San that roughly said the there we've as on report well Antonio essentially the Conference, data we Chris. Cancer study bar, on basically patients So are that patients point as see combination from level of response will other what on in we Trodelvy, existing as is data To who your the KEYTRUDA. with XX relevant

forward. So to XX% be have to interesting the something if that of order we XX% response then see take rate, in could we something very

be we'll in out that on patients. so reporting And XX

Importantly, it's not with competitive Trodelvy.

world pillars, preclinical system to of tumor increase that appears be on applied removed As something The there with and to neoantigen tolerated. to and, something systems them to checkpoints. that And and is in to you by next safe the and very is antigen the do the look and activate now what subsequently, orally able Many -- adaptive approaches Trodelvy in innate clinical delivered a immune is obviously, break early and complementary. way oncology immune the there's a our IO something it's at programs EDPXXXX is that's with tumor data several of well microenvironment. wave essentially know, Chris, we're based Things have that we of three the like current the cells. exposure

fit a going it's IO nice So the that are on in very other things with world.

that's what see in we'll I we rate, similar be very principle, reporting as systemic of it on. later-stage And described. supporting in consistent what clinical would, still trials. potentially to something said, Trodelvy immunity, terms if in that's potentially out with and then something So interesting interesting going at something response just support see if I've we to Obviously, terms activation lower a level, of of is

what there. that's for waiting we're So

then I'll neuro address, inflam. Let talk neuroinflammation. can EV can you about Mark, anything, just me on to, your maybe get Mark, you Duncan pass the there's can response respond And over -- first, to talk don't and who about if

Mark Bodmer

Sure. here. Chris, Mark

is Actually, bacteria vesicles product part of the into natural So throw it's component normally the fermentation. are because we the drug extracellular the shed medium. away a the from the

part cells, a about it. by of we in straightforward. and harvest we filtration, types context in And are regulatory answer these centrifugation questions in your of with so discussed with that the have rather content part of recognize than regulatory vesicles the I'm have as the fairly purify in And in likely we clinic mind that to they outcomes U.K., authorities, be and And going questions extracellular were it that's whole medium. I harvesting already the mixture part because positive it's to because you what of and U.S. both or the using very a products in asking microbe. the suspect of we the purity

different trying development are orally mammalian look to because the or instance, you'll actually, preclinical be a and because purity So would beneficial to we natural inject be, were which do the from exosome for by these toxicology than for testing. moment parenteral intravenously for we route. the preclinical some had we recall, requirements haven't it any as are hugely at completely to different delivered, requirements And is the they making have if products, other EVs microbes, don't

microbes. So at comment little other a per where higher. liter fermentation, pretty come, for we EVs the itself. and the the may as same will bit there's It scale to these of actually microbes. it's the the permissive for product even which look similar for is whole dose a essentially it the is that's issue cost One path drug are as that -- about things If yield be

some the the changes parts moment so at downstream manufacturing to got look a parent It requirements. are the not we've doing hairball EVs in at But And efficacy, mix conference then more one-for-one the differences shortly bacterium. proteins represented a processing we bit. the It's So content, way the which grab of see of the that. bacterium looking showing basically in the haven't we're a at maybe data try scale and changed our in just own content the highly the the of lot it's differences much to matching, that molecular to pharmacodynamics suspect EV of the and course, the of the microbe and you'll EV our we're I more we're versus in content. with get between due whole seeing and to and EV And rest. glycolipids SITC it's -- its And of do and the to around. other the target. to ability macro the

we where I that's So are there. that that. question your with hope answers

Chris Howerton

basically Yes. form? a clarification maybe Mark, very product capsule? Is in -- the brief it's but it's dosage sorry, And a just in that lyophilized a I'm

Mark Bodmer

product. straight disbursements that actually the a microbes in with microbes takes do. and Yes, sorry. the excipients EVs fundamentally are process. There it's It questions same we the same lyophilization at in all that but way transferring the lyophilized the differences things, and technology We're the over. Yes, looking formulation it's lyophilization the same are with and

Chris Howerton

very right. exciting. All Well, Okay.

Mark Bodmer

the actually. it's ago you where yes, to I for exciting, extraordinary very The we're able back reduce years something that briefing think think like this. on if to X -- it It's

the details it's this really it's really It's new behind a the months more well. -- of coming transformational, in scientific world. So as talk and some we'll about

And call the that to because the small a of I the formal of barrier part base a blood-brain sections, made with -- one about On to point that of spinal the see is SINTAX, the you activity the cross microbes in the part clearly. actually, activity that's ideas prospects companies bypasses central ago the on moment intestine statement the would neuro the actually very it there that on by need the fundamental doing cord inflammation, clear Actually, you based that's actually we've key can can public an or a there what small at nervous some Mayo entire And it We been the yet, nervous alone get cells central something. the profound hasn't intestinal on inflammatory in be the lot been access, do. for is our the can system doing development are put we our of statement. it domain for have significant Clinic. system, pharmacological company of And it how you us. does these the preclinically. published what a in data in been are but take mainstream part It has we and of enough collaborators

You asked of the question are different models the we've efficacy microbes. specifically EDPXXXX. in context where in maximum ones differentiation the and some preclinical robustness seen the of Actually,

microbes, activity. so actually give that preclinical activity, in the inflammatory which have more we robust on works, is pharmacology other X of have the consistent it but and others And superior basic We'll talk models, EDPXXXX us EDPXXXX. as part these about more things develop.

mentioned looking out neuro in classical differentiation control, some inflammation, didn't inflammatory degree look we that of to from we we're of to starting amongst and at core metabolism as So interestingly, product inflammatory of candidates core I just actually, some -- aspects we models. go in the inflammation metabolic as our see see

think. it leave I'll I so And there

Operator

of line with Thome Company. next & Joseph the from comes Our Cowen question

Joseph Thome

looks would The you're can the year, both we good, you programs. and remind you on XXXX forward other the one Or indication? COVID a just move When data data pulmonary see believe viral in this if from for this looks role you outside do studies, be the conditions? in here, then strong? with an you atopic indication? forward? thinking is first XXXX COVID-XX dermatitis in a If decision further kind from the both of look next make about the of there's before us effective will the area committing would XXXX And if data how moving And of focus

Balkrishan Gill

Thanks, Joe.

our driving different forward. are different for they're we're in manufacturing, why XXXX So how and in has linked and and small always the microbes look other XXXX of, been strategy inflammation differentiated on gut, to space, resolution which and question, to are to in the first terms the ways, inflammatory the example, taking at that's intestine in linked behavior

is resolving which both pathways. in to we're drives and to the mechanisms forward Obviously, see question XXXX. diseases the looking in then way the potent we going they're it's what same what let's both your going answer happens work is preclinical at if like different it's So data potent it very atopic devil in aggressively, with and antibodies, the to dermatitis, different, we'll be inflammation continue And refer still targeting sometimes to details, move to in on different it XXXX is. are but responses models. The they're see but and

moment, Joe. got riches see very on the So that embarrassment But anti-inflammatory of X of mechanisms. data, we have in to somewhat an we've work agents potent at different the having

hyperinflammation So we'll if we're see reveals viral of why in it's killing a viral example, resolve response relevant what of theory the as to which hyperinflammation COVID-XX. the infections, causes significant Joe, influenza, other for know, infections, beyond, there. your XXXX looking and number in in that because serious number including is the the progression a driver that a suggests, world, broad numbers very in areas. principle is as to core in other COVID, to of the and you a pulmonary other got we utility see at of as as COVID, know, you On question same still is number of data And people of XXXX, to

look absolutely, yes, positive see we'll So areas results in COVID-XX. if we into other

Operator

Matthew the from And Capital BMO of Markets. our next line question Luchini with comes

Unidentified Analyst

on progress. for the [ph] Jen This Congrats is Matthew. on

geographic two for when to sites many does color Could coming guys doing provide -- that sites in expansion? questions guys a there's they're in some trial Like going change the along how you makeup of are terms be the And in added? just And me. way? are study of being Just coming mean what on some online? you

Balkrishan Gill

hear good Jen, voice. your to

me I'll let Jen. question then step back bit, and little So your a answer directly,

not world other unpredictable. in have essentially rapid obviously, accelerated up been So COVID-XX ourselves and to we geographies. now. the of complex absolutely new multiple discussions is exploring is in and right but recruitment sites What just doing we've up U.K. the opening set ongoing for And

study. but platform their working led you by know, part closely U.K. is a of As Addenbrooke's. with them, this very study it's We're

to in more be not-too-distant internationally expand COVID-XX to And not me more future, we'll Jen areas some be other . in also to say right U.K. the the significant. in the for of So just than able sites expect I where are now don't think we it's I obvious but looking say appropriate to continues

Unidentified Analyst

my And how us AD? could psoriasis Phase question remind you accelerate II trial other the it. helped Got is development in

Balkrishan Gill

Duncan, sure. Yes, take do want you that one? to

Duncan McHale

Sure. take program Thanks, of lot dermatitis. psoriasis atopic a there's learnings EDPXXXX able for the for we Obviously, from question. will Jen be to the that [ph]

very actually I with short, from information awful think, to perspective. lot similar from tolerability the data safety will the our about that response provide dose ongoing populations across extrapolate is cohort just Phase of completely very dose Also of data combined as the that's these an in all well. likely Ib currently

from in able fact, those safety, So both and, the we'll to program. the tolerability atopic take psoriasis to efficacy be apply learnings and dermatitis

Operator

I'll [Operator turn Instructions]. back further call the any I'm questions. over closing showing not for remarks. now

Balkrishan Gill

doing. continued Thanks to everyone, attention very what much, we're for

incredibly the with exciting vesicles well disease platform an extracellular clinical of today's terms our the as we're as progress on biology. areas as this advancing call, of progress as readouts moving heard time, you of in is well in terms in both other forward As and

So much. Evelo, keeping Thank updated continued look the and you very as to we go attention you appreciate we forward. forward to

Operator

and does this Ladies program. conclude gentlemen, the

great Thank may participating. Everyone, you You now day. disconnect. for have a

Evelo Biosciences (EVLO) 1 Nov 202020 Q3 Earnings call transcript